Acumen Pharmaceuticals, Inc. ABOS 深 滬
等待開盤 11-04 09:30:00 美东时间
0.2344
-0.005
-2.21%
華盛通- 最 高0.2481
- 今 開0.2397
- 成交量 601.12万股
- 最 低 0.225
- 昨 收 0.2397
- 總市值 1.70万
- 52周最高 3.60
- 市盈率 靜 --
- 換手率 8311.17%
- 52周最低 0.198
- 委 比 -98.06%
- 總股本 7.23万
- 歷史最高 26.98
- 量 比 0.28
- 振 幅 9.64%
- 歷史最低 0.198
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅2250.23%！艾伯维获大摩等多家大行上调目标价，最高340美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从50美元升至51美元；HC Wainwright & Co.：上调伊诺维奥制药评级至"买入"，目标价5美元
11-03 18:20
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG cut the price target for Acumen Pharmaceuticals Inc (NASDAQ:ABOS) from $8 to $1. BTIG analyst Thomas Shra...
11-02 21:26
美股大行评级 | 潜在涨幅332.55%！Viking Therapeutics获上调目标价至118美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至118美元；Canaccord Genuity：维持Aclaris Therapeutics"买入"评级，目标价从10美元升至13美元
11-02 18:53
美股夜盘 | Acumen Pharmaceuticals, Inc.暴泻89.82%，最新股价0.23美元
Acumen Pharmaceuticals, Inc.暴泻89.82%，报0.23美元
11-02 09:17
Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1
Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.
10-31 04:34
Acumen Pharmaceuticals Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals (NASDAQ:ABOS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.ben...
10-26 20:41
Acumen Pharmaceuticals Q3 EPS $(0.35) Beats $(0.37) Estimate
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 20.45 percent increase over losses of $(0.44) per share from the same period last year.
10-26 19:02
Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present three key poster presentations at the upcoming 19th Annual Clini...
10-22 19:36
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.
09-17 01:20
